Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Appendiceal Neoplasms | 6 | 2024 | 234 | 1.040 |
Why?
|
Colitis | 4 | 2022 | 340 | 0.640 |
Why?
|
Carcinoma, Pancreatic Ductal | 4 | 2023 | 1755 | 0.440 |
Why?
|
Colorectal Neoplasms | 5 | 2023 | 3583 | 0.340 |
Why?
|
Pancreatic Neoplasms | 6 | 2023 | 5101 | 0.330 |
Why?
|
PTEN Phosphohydrolase | 1 | 2012 | 986 | 0.300 |
Why?
|
Adenocarcinoma | 5 | 2024 | 7793 | 0.290 |
Why?
|
Bile Duct Neoplasms | 2 | 2021 | 495 | 0.250 |
Why?
|
Cholangiocarcinoma | 2 | 2021 | 495 | 0.240 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 4980 | 0.230 |
Why?
|
Peritoneal Neoplasms | 2 | 2023 | 828 | 0.220 |
Why?
|
Anus Neoplasms | 2 | 2017 | 412 | 0.220 |
Why?
|
Pancreatitis, Chronic | 1 | 2023 | 117 | 0.220 |
Why?
|
DNA Mismatch Repair | 2 | 2023 | 268 | 0.210 |
Why?
|
Interleukin-6 | 2 | 2022 | 1032 | 0.190 |
Why?
|
Biopsy | 5 | 2020 | 3446 | 0.190 |
Why?
|
Enterocolitis, Neutropenic | 1 | 2020 | 19 | 0.180 |
Why?
|
Diarrhea | 2 | 2021 | 689 | 0.170 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2023 | 436 | 0.170 |
Why?
|
Eosinophilia | 1 | 2021 | 176 | 0.170 |
Why?
|
Intestinal Perforation | 1 | 2020 | 102 | 0.170 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2020 | 170 | 0.170 |
Why?
|
Hyperthermia, Induced | 1 | 2023 | 512 | 0.160 |
Why?
|
Genomics | 3 | 2021 | 2746 | 0.160 |
Why?
|
Neoplasms | 5 | 2023 | 15198 | 0.160 |
Why?
|
Percutaneous Coronary Intervention | 1 | 2023 | 347 | 0.150 |
Why?
|
Middle Aged | 21 | 2024 | 86545 | 0.150 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2020 | 565 | 0.150 |
Why?
|
Biomarkers, Tumor | 4 | 2024 | 10348 | 0.150 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 108 | 0.150 |
Why?
|
Pancreaticoduodenectomy | 2 | 2018 | 692 | 0.140 |
Why?
|
Antigens, CD | 1 | 2021 | 1382 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2016 | 481 | 0.140 |
Why?
|
Stem Cell Factor | 1 | 2016 | 89 | 0.140 |
Why?
|
Aged | 17 | 2024 | 70365 | 0.140 |
Why?
|
Antibodies, Monoclonal | 2 | 2021 | 4386 | 0.140 |
Why?
|
Smad2 Protein | 1 | 2016 | 88 | 0.140 |
Why?
|
Esophagectomy | 1 | 2020 | 911 | 0.130 |
Why?
|
Bile Ducts | 1 | 2016 | 112 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1350 | 0.130 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2021 | 1054 | 0.130 |
Why?
|
Pseudomyxoma Peritonei | 1 | 2015 | 38 | 0.130 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2016 | 293 | 0.120 |
Why?
|
Gastrointestinal Diseases | 1 | 2019 | 587 | 0.120 |
Why?
|
Microsatellite Instability | 3 | 2023 | 400 | 0.120 |
Why?
|
Male | 21 | 2023 | 123366 | 0.120 |
Why?
|
Nonsense Mediated mRNA Decay | 1 | 2014 | 38 | 0.120 |
Why?
|
Immunohistochemistry | 5 | 2021 | 7545 | 0.120 |
Why?
|
Mesothelioma | 1 | 2019 | 542 | 0.120 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2014 | 103 | 0.120 |
Why?
|
Aged, 80 and over | 9 | 2024 | 29996 | 0.120 |
Why?
|
Tissue Array Analysis | 2 | 2012 | 762 | 0.120 |
Why?
|
Calcinosis | 1 | 2017 | 426 | 0.120 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 469 | 0.120 |
Why?
|
Cholestasis | 1 | 2016 | 203 | 0.120 |
Why?
|
Liver Neoplasms | 3 | 2021 | 4562 | 0.110 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2023 | 1251 | 0.110 |
Why?
|
Humans | 30 | 2024 | 262305 | 0.110 |
Why?
|
Prognosis | 7 | 2023 | 21745 | 0.110 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2017 | 483 | 0.110 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2017 | 520 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 1247 | 0.110 |
Why?
|
Female | 20 | 2023 | 142324 | 0.110 |
Why?
|
Fibromatosis, Aggressive | 1 | 2012 | 108 | 0.100 |
Why?
|
Adult | 13 | 2021 | 78183 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 15881 | 0.100 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2017 | 5435 | 0.100 |
Why?
|
Alternative Splicing | 1 | 2014 | 581 | 0.100 |
Why?
|
Retrospective Studies | 10 | 2024 | 38022 | 0.090 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2012 | 221 | 0.090 |
Why?
|
Abdominal Neoplasms | 1 | 2012 | 231 | 0.090 |
Why?
|
Survival Rate | 5 | 2023 | 12240 | 0.090 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2021 | 3264 | 0.090 |
Why?
|
Immunotherapy, Adoptive | 1 | 2019 | 1766 | 0.090 |
Why?
|
Cytoreduction Surgical Procedures | 2 | 2023 | 474 | 0.080 |
Why?
|
Young Adult | 6 | 2021 | 21507 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2017 | 978 | 0.080 |
Why?
|
Salvage Therapy | 1 | 2017 | 2060 | 0.080 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1900 | 0.080 |
Why?
|
Trans-Activators | 1 | 2014 | 1557 | 0.080 |
Why?
|
Lymphoma | 1 | 2016 | 1472 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 7567 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5185 | 0.070 |
Why?
|
Colonoscopy | 2 | 2021 | 518 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2017 | 10070 | 0.070 |
Why?
|
Esophageal Neoplasms | 1 | 2020 | 3170 | 0.070 |
Why?
|
Pancreatectomy | 2 | 2023 | 654 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 4904 | 0.070 |
Why?
|
Mutation | 4 | 2020 | 15176 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 5155 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2020 | 4355 | 0.060 |
Why?
|
Neoplasm Grading | 2 | 2020 | 1750 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2016 | 2027 | 0.060 |
Why?
|
Carcinoembryonic Antigen | 1 | 2024 | 223 | 0.060 |
Why?
|
Frozen Sections | 1 | 2023 | 105 | 0.060 |
Why?
|
CA-19-9 Antigen | 1 | 2024 | 146 | 0.060 |
Why?
|
Risk Factors | 4 | 2021 | 17626 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6223 | 0.050 |
Why?
|
CA-125 Antigen | 1 | 2024 | 226 | 0.050 |
Why?
|
Leucovorin | 1 | 2023 | 333 | 0.050 |
Why?
|
Liver | 3 | 2017 | 2902 | 0.050 |
Why?
|
Databases, Factual | 2 | 2020 | 2236 | 0.050 |
Why?
|
V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2021 | 29 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 2288 | 0.050 |
Why?
|
Observer Variation | 1 | 2023 | 671 | 0.050 |
Why?
|
Mucins | 1 | 2023 | 285 | 0.050 |
Why?
|
Cross-Over Studies | 1 | 2023 | 462 | 0.050 |
Why?
|
Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 77 | 0.050 |
Why?
|
B7 Antigens | 1 | 2021 | 84 | 0.050 |
Why?
|
Loss of Function Mutation | 1 | 2021 | 132 | 0.050 |
Why?
|
Myeloid Cells | 1 | 2022 | 263 | 0.050 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 43 | 0.050 |
Why?
|
Chromogranins | 1 | 2020 | 85 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2020 | 3549 | 0.050 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2021 | 216 | 0.050 |
Why?
|
Prospective Studies | 3 | 2023 | 12927 | 0.050 |
Why?
|
Perioperative Period | 1 | 2021 | 155 | 0.050 |
Why?
|
Pancreas | 1 | 2023 | 716 | 0.040 |
Why?
|
Thioguanine | 1 | 2019 | 68 | 0.040 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 336 | 0.040 |
Why?
|
Safety | 1 | 2021 | 464 | 0.040 |
Why?
|
Mortality | 1 | 2021 | 346 | 0.040 |
Why?
|
Asparaginase | 1 | 2019 | 184 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 5123 | 0.040 |
Why?
|
Immunotherapy | 2 | 2022 | 3349 | 0.040 |
Why?
|
Fluorouracil | 1 | 2023 | 1946 | 0.040 |
Why?
|
Digestive System Surgical Procedures | 1 | 2021 | 275 | 0.040 |
Why?
|
Daunorubicin | 1 | 2019 | 302 | 0.040 |
Why?
|
Oncogenes | 1 | 2021 | 669 | 0.040 |
Why?
|
Sex Distribution | 1 | 2019 | 496 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2021 | 1382 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2022 | 656 | 0.040 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 14301 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2018 | 13670 | 0.040 |
Why?
|
Age Distribution | 1 | 2019 | 703 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2021 | 33029 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2021 | 1064 | 0.040 |
Why?
|
Patient-Specific Modeling | 1 | 2017 | 28 | 0.040 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2020 | 375 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2017 | 6105 | 0.040 |
Why?
|
Genes, ras | 1 | 2020 | 667 | 0.040 |
Why?
|
Risk Assessment | 2 | 2020 | 6900 | 0.040 |
Why?
|
Radiation Tolerance | 1 | 2020 | 629 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2017 | 8880 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2019 | 11570 | 0.040 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2021 | 1040 | 0.040 |
Why?
|
Hep G2 Cells | 1 | 2016 | 155 | 0.030 |
Why?
|
Colon | 1 | 2020 | 673 | 0.030 |
Why?
|
Gastritis | 1 | 2019 | 372 | 0.030 |
Why?
|
Mice | 3 | 2022 | 34391 | 0.030 |
Why?
|
Gastric Mucosa | 1 | 2019 | 613 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2021 | 2303 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2019 | 1363 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 522 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2021 | 1083 | 0.030 |
Why?
|
Time Factors | 2 | 2020 | 12985 | 0.030 |
Why?
|
Bilirubin | 1 | 2016 | 221 | 0.030 |
Why?
|
Gene Components | 1 | 2014 | 16 | 0.030 |
Why?
|
Cell Cycle Checkpoints | 1 | 2016 | 278 | 0.030 |
Why?
|
Pilot Projects | 1 | 2021 | 2805 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2017 | 1516 | 0.030 |
Why?
|
DNA-Binding Proteins | 2 | 2017 | 4788 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2021 | 14558 | 0.030 |
Why?
|
In Situ Nick-End Labeling | 1 | 2014 | 446 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2021 | 1826 | 0.030 |
Why?
|
RNA Helicases | 1 | 2014 | 101 | 0.030 |
Why?
|
Cohort Studies | 2 | 2019 | 9288 | 0.030 |
Why?
|
Gene Expression | 1 | 2021 | 3563 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 1417 | 0.030 |
Why?
|
Cytarabine | 1 | 2019 | 1976 | 0.030 |
Why?
|
Inflammation | 1 | 2022 | 2514 | 0.030 |
Why?
|
Syndrome | 1 | 2016 | 1352 | 0.030 |
Why?
|
Mutagenesis | 1 | 2014 | 482 | 0.030 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 2860 | 0.030 |
Why?
|
Tumor Burden | 1 | 2018 | 1991 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2017 | 14917 | 0.030 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2012 | 104 | 0.030 |
Why?
|
Hospitalization | 1 | 2021 | 2120 | 0.030 |
Why?
|
Adolescent | 3 | 2019 | 31270 | 0.030 |
Why?
|
Animals | 3 | 2022 | 59487 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8889 | 0.030 |
Why?
|
RNA Interference | 1 | 2016 | 1411 | 0.030 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2012 | 157 | 0.030 |
Why?
|
Chromatin | 1 | 2017 | 950 | 0.020 |
Why?
|
Estrogen Receptor beta | 1 | 2012 | 155 | 0.020 |
Why?
|
RNA, Long Noncoding | 1 | 2017 | 601 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 973 | 0.020 |
Why?
|
Age Factors | 1 | 2020 | 5386 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 1221 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 2215 | 0.020 |
Why?
|
Mitochondria | 1 | 2017 | 1282 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2012 | 577 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2012 | 481 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2014 | 1498 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 3076 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2016 | 1122 | 0.020 |
Why?
|
Mass Screening | 1 | 2018 | 1505 | 0.020 |
Why?
|
Incidence | 1 | 2019 | 5714 | 0.020 |
Why?
|
Texas | 1 | 2020 | 6311 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 4746 | 0.020 |
Why?
|
Quality of Life | 1 | 2022 | 4583 | 0.020 |
Why?
|
Cell Movement | 1 | 2016 | 2462 | 0.020 |
Why?
|
beta Catenin | 1 | 2012 | 687 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3983 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2016 | 3127 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 3632 | 0.020 |
Why?
|
Base Sequence | 1 | 2014 | 4887 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2017 | 4846 | 0.020 |
Why?
|
Estrogen Receptor alpha | 1 | 2012 | 700 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 2182 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2017 | 6130 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 6062 | 0.020 |
Why?
|
DNA Methylation | 1 | 2017 | 2671 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 2480 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2017 | 3317 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 3233 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2017 | 10023 | 0.020 |
Why?
|
Disease Progression | 1 | 2016 | 6696 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2016 | 7241 | 0.010 |
Why?
|
Transcription Factors | 1 | 2017 | 5254 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 11971 | 0.010 |
Why?
|